Since our therapeutic strategy targets the molecular consequences of mTORC1 hyperactivation, which is mechanistically different from targeting the hyperactivated mTOR pathway by mTOR inhibitors, we reasoned that this strategy could prove to be a reliable treatment to rapamycin-resistant TSC2-null tumor cells. Here, TSC2 is linked to neoplasm.